Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
1,338
Views
0
CrossRef citations to date
0
Altmetric
Diabetes
Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial
Jean-Eric Tarridea Department of Health Research Methods, Evidence, and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, CanadaCorrespondence[email protected]
, Mansoor Husainb Ted Rogers Centre for Heart Research, Toronto General Hospital Research Institute, Toronto, Canada
, Andreas Andersenc Biostatistics GLP-1 and CV 1, Novo Nordisk A/S, Søborg, Denmark
, Jens Gundgaardd GEPA Early Asset Strategy, Novo Nordisk A/S, Søborg, Denmark
, Maria Luckeviche Patient Access, Novo Nordisk Canada Inc., Mississauga, Canada
, Thomas Markf Biostatistics Degludec, Novo Nordisk A/S, Søborg, Denmark
, Lily Wagnerg Novo Nordisk A/S, Søborg, Denmark
& Thomas R. Pieberh Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
show all
Pages 1318-1326
|
Received 26 Aug 2021, Accepted 04 Nov 2021, Published online: 24 Nov 2021
Related Research Data
Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.